share_log

424B5: Prospectus

424B5: Prospectus

424B5：募資說明書
美股SEC公告 ·  07/26 13:23
Moomoo AI 已提取核心訊息
60 Degrees Pharmaceuticals, Inc., listed on The Nasdaq Capital Market under the symbol 'SXTP', has announced an increase in the maximum aggregate gross sales price of its common stock to $2,190,416 through an At the Market Issuance Sales Agreement with WallachBeth Capital LLC. This increase, detailed in a prospectus supplement filed on July 26, 2024, amends previous registrations to allow for additional sales under the agreement. As of the filing date, 60 Degrees Pharmaceuticals has sold 7,525,879 shares for an aggregate gross sales price of $1,890,500.81. The company's outstanding common stock held by non-affiliates is valued at approximately $6,571,249, based on a share price of $0.351 as of June 7, 2024. The company adheres to the SEC's General Instruction I.B.6 of Form S-3, limiting sales to no more than one-third of their public float in a 12-month period, provided the public float remains below $75 million. Investors are advised to consider the risk factors outlined in the accompanying prospectus supplement and base prospectus, as well as other SEC filings.
60 Degrees Pharmaceuticals, Inc., listed on The Nasdaq Capital Market under the symbol 'SXTP', has announced an increase in the maximum aggregate gross sales price of its common stock to $2,190,416 through an At the Market Issuance Sales Agreement with WallachBeth Capital LLC. This increase, detailed in a prospectus supplement filed on July 26, 2024, amends previous registrations to allow for additional sales under the agreement. As of the filing date, 60 Degrees Pharmaceuticals has sold 7,525,879 shares for an aggregate gross sales price of $1,890,500.81. The company's outstanding common stock held by non-affiliates is valued at approximately $6,571,249, based on a share price of $0.351 as of June 7, 2024. The company adheres to the SEC's General Instruction I.B.6 of Form S-3, limiting sales to no more than one-third of their public float in a 12-month period, provided the public float remains below $75 million. Investors are advised to consider the risk factors outlined in the accompanying prospectus supplement and base prospectus, as well as other SEC filings.
60 Degrees Pharmaceuticals公司在納斯達克資本市場上的標的爲'SXTP'，通過與WallachBeth Capital LLC的市場發行銷售協議，宣佈將其普通股的最大總髮行數量增加至2,190,416美元。根據2024年7月26日提交的招股說明書補充文件，這一增長修改了先前的註冊，以允許協議下的額外銷售。截至提交日期，60 Degrees Pharmaceuticals公司已售出7,525,879股，總銷售價格爲1,890,500.81美元。該公司的非關聯人持有的普通股市值約爲6,571,249美元，根據2024年6月7日的股價0.351美元計算。公司遵守SEC表格S-3的一般指令I.b.6，限制在12個月內以不超過其公開流通股份的三分之一的銷售量進行銷售，前提是公開流通股份仍低於7500萬美元。建議投資者考慮隨附的招股說明書和基礎招股說明書以及其他SEC備案文件中概述的風險因素。
60 Degrees Pharmaceuticals公司在納斯達克資本市場上的標的爲'SXTP'，通過與WallachBeth Capital LLC的市場發行銷售協議，宣佈將其普通股的最大總髮行數量增加至2,190,416美元。根據2024年7月26日提交的招股說明書補充文件，這一增長修改了先前的註冊，以允許協議下的額外銷售。截至提交日期，60 Degrees Pharmaceuticals公司已售出7,525,879股，總銷售價格爲1,890,500.81美元。該公司的非關聯人持有的普通股市值約爲6,571,249美元，根據2024年6月7日的股價0.351美元計算。公司遵守SEC表格S-3的一般指令I.b.6，限制在12個月內以不超過其公開流通股份的三分之一的銷售量進行銷售，前提是公開流通股份仍低於7500萬美元。建議投資者考慮隨附的招股說明書和基礎招股說明書以及其他SEC備案文件中概述的風險因素。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息